ImmunityBio Expands ANKTIVA Access to Saudi Arabia
ImmunityBio, Inc. (IBRX) has expanded access to its immunotherapy drug ANKTIVA in Saudi Arabia, marking its first commercial use in the region. The therapy is approved for bladder cancer and metastatic non-small cell lung cancer. The company also secured $75 million in non-dilutive funding through an amended royalty agreement.
Tickers: $IBRX
Topics: ANKTIVA biotech immunotherapy market expansion Saudi Arabia